Form 4: Pfizer CEO Albert Bourla Reports Acquisition of Phantom Stock Units

Pfizer's Chairman and CEO, Albert Bourla, reported the acquisition of 17 phantom stock units through the company's Supplemental Savings Plan on July 31, 2024.

Summary

• On July 31, 2024, Albert Bourla, the Chairman & CEO of Pfizer Inc., acquired 17 phantom stock units through the Pfizer Supplemental Savings Plan (SSP).
• These units are settled in cash following the reporting person's separation from service and may be transferred into an alternative investment account at any time.
• Following the transaction, Bourla directly owns 678,116 shares of Pfizer common stock.
• The price per share for the phantom stock units was $30.54.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. It doesn't convey any specific positive or negative sentiment about the company's performance or prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common for executives of publicly traded companies. It provides transparency into the holdings of key personnel and their investment activity in the company's stock.

Comparison to Industry Standards

• Executive compensation packages often include stock options, restricted stock units (RSUs), or phantom stock units to align executive interests with shareholder value.
• Companies like Johnson & Johnson (JNJ) and Merck & Co. (MRK) also utilize similar equity-based compensation plans for their executives.
• The specific terms and conditions of these plans can vary, but the general purpose is to incentivize long-term performance and retention.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders.
• It provides transparency to shareholders regarding executive compensation and ownership.

Key Dates